Insulet (NASDAQ:PODD) Trading 4.9% Higher – Time to Buy?

Insulet Corporation (NASDAQ:PODD) rose 4.9% on Tuesday . The company traded as high as $145.87 and last traded at $146.5610. 92,700 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 1,310,668 shares. The stock had previously closed at $139.70.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet insiders have been net buyers over the past six months, including CEO Ashley McEvoy’s reported purchase of approximately 4,300 shares. Analysts also remain broadly constructive, with recent “Outperform” and “Overweight” ratings and a median price target substantially above the current trading level. Why Insulet Stock Is Down Today
• Neutral Sentiment: Multiple law firms are reminding shareholders that August 31, 2026 is the deadline to seek appointment as lead plaintiff in a federal class action involving investors who purchased Insulet securities during a period generally spanning February 21, 2025, through May 26, 2026. These notices are largely duplicative and do not represent a new judgment against the company. Insulet Shareholder Notice
• Negative Sentiment: The lawsuits allege that Insulet and certain executives violated federal securities laws by making misleading statements or omissions related to defective Omnipod manufacturing controls. The allegations have not been proven, but continued litigation could increase legal costs and investor uncertainty, particularly because the CEO and CFO are named as individual defendants in some filings. Insulet Securities Class Action Alert
• Negative Sentiment: Investors are also focused on weaker forward Omnipod growth expectations following the latest earnings update. Although Insulet exceeded quarterly earnings and revenue estimates, softer guidance and a prior medical-device correction affecting certain Pods have raised concerns about U.S. demand, manufacturing execution and recall-related risks. Why Insulet Stock Is Down Today

Analyst Upgrades and Downgrades

PODD has been the subject of a number of analyst reports. Bank of America cut their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Stifel Nicolaus cut their target price on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Truist Financial reaffirmed a “hold” rating and issued a $153.00 price target (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Benchmark lowered their price target on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Wells Fargo & Company lowered Insulet from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Stock Performance

The stock has a 50-day moving average of $154.96 and a 200 day moving average of $187.34. The firm has a market capitalization of $10.14 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current year.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC increased its holdings in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares in the last quarter. Cresset Asset Management LLC raised its holdings in Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 177 shares during the last quarter. Cerity Partners LLC lifted its position in Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. lifted its position in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina boosted its stake in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.